Literature DB >> 26085865

The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC).

Fred Saad1, Kim N Chi2, Antonio Finelli3, Sebastien J Hotte4, Jonathan Izawa5, Anil Kapoor6, Wassim Kassouf7, Andrew Loblaw8, Scott North9, Ricardo Rendon10, Alan So11, Nawaid Usmani12, Eric Vigneault13, Neil E Fleshner3.   

Abstract

Agents that have shown improvements in survival in mCRPC now include abiraterone, enzalutamide, docetaxel, cabazitaxel and radium-223. Bone supportive agents and palliative radiation continue to play an important role in the overall management of mCRPC. Given the complexity, variety and importance of optimizing the use of these agents, a multidisciplinary team approach is highly recommended.

Entities:  

Year:  2015        PMID： 26085865      PMCID： PMC4455631          DOI： 10.5489/cuaj.2526

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


  32 in total

1.  Prednisone monotherapy in asymptomatic hormone refractory prostate cancer.

Authors:  Daniel Y C Heng; Kim N Chi
Journal:  Can J Urol       Date:  2006-12       Impact factor: 1.344

2.  Increased survival with enzalutamide in prostate cancer after chemotherapy.

Authors:  Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono
Journal:  N Engl J Med       Date:  2012-08-15       Impact factor: 91.245

3.  First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?

Authors:  Jorg Michels; Trina Montemurro; Nevin Murray; Christian Kollmannsberger; Kim Nguyen Chi
Journal:  Cancer       Date:  2006-03-01       Impact factor: 6.860

4.  Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial.

Authors:  A T Porter; A J McEwan
Journal:  Semin Oncol       Date:  1993-06       Impact factor: 4.929

5.  Development of a second-generation antiandrogen for treatment of advanced prostate cancer.

Authors:  Chris Tran; Samedy Ouk; Nicola J Clegg; Yu Chen; Philip A Watson; Vivek Arora; John Wongvipat; Peter M Smith-Jones; Dongwon Yoo; Andrew Kwon; Teresa Wasielewska; Derek Welsbie; Charlie Degui Chen; Celestia S Higano; Tomasz M Beer; David T Hung; Howard I Scher; Michael E Jung; Charles L Sawyers
Journal:  Science       Date:  2009-04-09       Impact factor: 47.728

6.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

Authors:  Daniel P Petrylak; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Donna Berry; Carol Moinpour; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

7.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

8.  Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group.

Authors:  G O N Oosterhof; J T Roberts; Th M de Reijke; S A Engelholm; S Horenblas; H von der Maase; N Neymark; M Debois; L Collette
Journal:  Eur Urol       Date:  2003-11       Impact factor: 20.096

9.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Authors:  Howard I Scher; Susan Halabi; Ian Tannock; Michael Morris; Cora N Sternberg; Michael A Carducci; Mario A Eisenberger; Celestia Higano; Glenn J Bubley; Robert Dreicer; Daniel Petrylak; Philip Kantoff; Ethan Basch; William Kevin Kelly; William D Figg; Eric J Small; Tomasz M Beer; George Wilding; Alison Martin; Maha Hussain
Journal:  J Clin Oncol       Date:  2008-03-01       Impact factor: 44.544

Review 10.  Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.

Authors:  Terrence H Diamond; Celestia S Higano; Matthew R Smith; Theresa A Guise; Frederick R Singer
Journal:  Cancer       Date:  2004-03-01       Impact factor: 6.860
View more
  34 in total

1.  Followup imaging studies in metastatic castration-resistant prostate cancer: An individualized approach.

Authors:  Myuran Thana; Lori A Wood
Journal:  Can Urol Assoc J       Date:  2019-06       Impact factor: 1.862

Review 2.  Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer.

Authors:  Laurence Klotz; Rodney H Breau; Loretta L Collins; Martin E Gleave; Tom Pickles; Frederic Pouliot; Fred Saad
Journal:  Can Urol Assoc J       Date:  2017 Jan-Feb       Impact factor: 1.862

3.  A Retrospective Analysis of the First 41 mCRPC Patients with Bone Pain Treated with Radium-223 at the National Institute of Oncology in Hungary.

Authors:  Zs Küronya; I Sinkovics; P Ágoston; K Bíró; I Bodrogi; I Böde; M Dank; F Gyergyay; T Vajdics; Zs Kolonics; K Nagyiványi; Á Rúzsa; L Géczi
Journal:  Pathol Oncol Res       Date:  2017-01-10       Impact factor: 3.201

4.  The burden of symptomatic skeletal events in castrate-resistant prostate cancer patients with bone metastases at three Canadian uro-oncology centres.

Authors:  Fred Saad; Neil E Fleshner; Alan So; Jacques Le Lorier; Louise Perrault; Melanie Poulin-Costello; Raina Rogoza; Ewan J D Robson
Journal:  Can Urol Assoc J       Date:  2018-06-19       Impact factor: 1.862

Review 5.  A primer on tumour immunology and prostate cancer immunotherapy.

Authors:  Runhan Ren; Madhuri Koti; Thomas Hamilton; Charles H Graham; Jasmir G Nayak; Jas Singh; Darrel E Drachenberg; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2016 Jan-Feb       Impact factor: 1.862

Review 6.  Contemporary agents in the management of metastatic castration-resistant prostate cancer.

Authors:  Anil Kapoor; Christopher Wu; Bobby Shayegan; Adrian P Rybak
Journal:  Can Urol Assoc J       Date:  2016-12-12       Impact factor: 1.862

Review 7.  Management algorithms for metastatic prostate cancer.

Authors:  Shawn Malone; Bobby Shayegan; Naveen S Basappa; Kim Chi; Henry J Conter; Robert J Hamilton; Sebastien J Hotte; Fred Saad; Alan I So; Laura Park-Wyllie; Huong Hew; Deanna McLeod; Geoffrey Gotto
Journal:  Can Urol Assoc J       Date:  2019-04-26       Impact factor: 1.862

8.  Treatment patterns and trends in patients dying of prostate cancer in Quebec: a population-based study.

Authors:  A Dragomir; J Rocha; M Vanhuyse; F L Cury; W Kassouf; J Hu; A G Aprikian
Journal:  Curr Oncol       Date:  2017-08-31       Impact factor: 3.677

9.  Testosterone suppression in the treatment of recurrent or metastatic prostate cancer - A Canadian consensus statement.

Authors:  Laurence Klotz; Bobby Shayegan; Chantal Guillemette; Loretta L Collins; Geoffrey Gotto; Dominique Guérette; Marie-Paule Jammal; Tom Pickles; Patrick O Richard; Fred Saad
Journal:  Can Urol Assoc J       Date:  2017-12-19       Impact factor: 1.862

10.  Disparity in public funding of therapies for metastatic castrate-resistant prostate cancer across Canadian provinces.

Authors:  Dixon T S Woon; Thenappan Chandrasekar; Lorne Aaron; Naveen S Basappa; Kim N Chi; Henry J Conter; Geoffrey Gotto; Sebastien J Hotte; Shawn Malone; Fred Saad; Bobby Shayegan; Laura Park-Wyllie; Robert J Hamilton
Journal:  Can Urol Assoc J       Date:  2018-07-16       Impact factor: 1.862
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.